计算分析预测EGFR突变对激酶抑制剂的差异化敏感性
该研究对298个临床报道的EGFR激酶结构域点突变进行大规模计算分析,通过分子对接预测每个突变对7种激酶抑制剂的敏感性,并与ATP相对结合亲和力比较。预测结果与已发表的临床、实验和计算数据良好相关,单突变和复合突变对第一代和下一代抑制剂的敏感性存在差异。研究为大量不常见EGFR突变提供了预测性药物敏感性谱,可能辅助临床制定突变特异性治疗策略。
要点
- 计算分析覆盖298个EGFR激酶结构域点突变和7种激酶抑制剂。
- 预测的抑制剂敏感性谱与已发表的临床、实验和计算数据良好相关。
- 单突变和复合突变对第一代和下一代激酶抑制剂显示差异化敏感性。
核心结论
- 该研究为大量不常见EGFR突变提供了对多种抑制剂的预测药物敏感性谱,可能帮助临床医生决定突变特异性治疗策略。
研究设计与样本
- 对临床报道的298个EGFR激酶结构域点突变进行大规模计算分析,通过分子对接确定每个突变对7种激酶抑制剂的药物敏感性谱,并计算每个突变对每种药物相对于ATP的相对抑制剂结合亲和力。
主要发现
- 本研究预测的一组先前已表征突变的抑制剂敏感性谱与已发表的临床、实验和计算数据良好相关。
- 单突变和复合突变对第一代和下一代激酶抑制剂均表现出差异化的抑制剂敏感性。
临床怎么用
- 预测的药物敏感性谱可能帮助临床医生为携带不常见EGFR突变的患者决定突变特异性治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: A significant proportion of patients with lung cancer carry mutations in the EGFR kinase domain. The presence of a deletion mutation in exon 19 or L858R point mutation in the EGFR kinase domain has been shown to cause enhanced efficacy of inhibitor treatment in patients with NSCLC. Several less frequent (uncommon) mutations in the EGFR kinase domain with potential implications in treatment response have also been reported. The role of a limited number of uncommon mutations in drug sensitivity was experimentally verified. However, a huge number of these mutations remain uncharacterized for inhibitor sensitivity or resistance. METHODS: A large-scale computational analysis of clinically reported 298 point mutants of EGFR kinase domain has been performed, and drug sensitivity profiles for each mutant toward seven kinase inhibitors has been determined by molecular docking. In addition, the relative inhibitor binding affinity toward each drug as compared with that of adenosine triphosphate was calculated for each mutant. RESULTS: The inhibitor sensitivity profiles predicted in this study for a set of previously characterized mutants correlated well with the published clinical, experimental, and computational data. Both the single and compound mutations displayed differential inhibitor sensitivity toward first- and next-generation kinase inhibitors. CONCLUSIONS: The present study provides predicted drug sensitivity profiles for a large panel of uncommon EGFR mutations toward multiple inhibitors, which may help clinicians in deciding mutant-specific treatment strategies.
引用
- Akula S, Kamasani S, Sivan SK, et al. Computational Analysis of Epidermal Growth Factor Receptor Mutations Predicts Differential Drug Sensitivity Profiles toward Kinase Inhibitors. J Thorac Oncol. 2018. PMID: 29369805. doi:10.1016/j.jtho.2018.01.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。